articleTop 1% cited

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

Arthritis & Rheumatism · 1998 · Vol. 41(12) · pp. 2196–2204

Barry Bresnihan✉Jos� Maria Alvaro-Gracia(Hospital Universitario de La Princesa)Mark Cobby(Frenchay Hospital)Michael Doherty(Nottingham City Hospital)Z Domljan(University Hospital Centre Zagreb)Paul Emery(Leeds General Infirmary)George Nuki(University of Edinburgh)Karel Pavelká(Institute of Rheumatology)Rolf Rau(Fachklinik 360°)Blaž Rozman(Ljubljana University Medical Centre)Iain Watt(Bristol Royal Infirmary)Bryan Williams(University Hospital of Wales)Roger Aitchison(Amgen (United States))Dorothy McCabe(Amgen (United States))Predrag Musikic(Amgen (Netherlands))

View via DOI Publisher page

Abstract

This study confirmed both the efficacy and the safety of IL-1Ra in a large cohort of patients with active and severe RA. IL-1Ra is the first biologic agent to demonstrate a beneficial effect on the rate of joint erosion.

Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Systemic Lupus Erythematosus ResearchMedicineRheumatoid arthritisErythrocyte sedimentation ratePlaceboInternal medicineRheumatologyVisual analogue scalePrednisoloneAdverse effectArthritis

MeSH terms

AdolescentAdultAgedArthritis, RheumatoidDouble-Blind MethodFemaleHandHumansInjections, Intra-ArticularJointsMaleMiddle AgedRadiographyRecombinant ProteinsRheumatoid Factor

Citations

971

FWCI

37.46

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Overview of the <scp>IL</scp>‐1 family in innate inflammation and acquired immunity